Antimicrobial resistance remains one of the biggest threats to global health. A recent study published in Clinical Microbiology and Infection evaluates the in vitro activity of cefepime-enmetazobactam, a novel β-lactam/β-lactamase inhibitor combination, against carbapenem-resistant Gram-negative pathogens.
Key Findings: High efficacy against OXA-48-like carbapenemase-producing Enterobacterales, comparable to ceftazidime-avibactam.- Limited added value against Pseudomonas aeruginosa and Acinetobacter baumannii.
- Potential as an alternative treatment for infections caused by resistant bacteria, particularly OXA-48 producers.
This promising combination may help reduce reliance on existing β-lactamase inhibitors and limit the spread of antimicrobial resistance. Future in vivo studies will be crucial to confirm its clinical effectiveness.
